bendamustine hydrochloride has been researched along with Hemolysis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cazzola, M | 1 |
| Callum, J; Lin, Y; Yan, M | 1 |
| Gothwal, A; Gupta, U; Khan, I; Qayum, A; Sharma, AK; Singh, SK | 1 |
3 other study(ies) available for bendamustine hydrochloride and Hemolysis
| Article | Year |
|---|---|
Introduction to a How I Treat series on acquired hemolytic anemia.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Bendamustine Hydrochloride; Complement Inactivating Agents; Disease Management; Hemolysis; Humans; Immunologic Factors; Rituximab; Splenectomy; Steroids | 2021 |
Hyperhemolysis associated with marginal zone lymphoma.
Topics: Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hemoglobins; Hemolysis; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Reticulocyte Count; Rituximab; Transfusion Reaction; Treatment Outcome | 2015 |
Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of bendamustine.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Erythrocytes; Female; Hemolysis; Humans; Kinetics; Male; MCF-7 Cells; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols | 2016 |